194 related articles for article (PubMed ID: 26032616)
21. The Association between Paradoxical Vocal Fold Motion and Dysphonia in Adolescents.
Fulton NM; Drake K; Childes JM; Ziegler A; Schindler JS; Graville DJ; Palmer AD
Folia Phoniatr Logop; 2020; 72(5):378-388. PubMed ID: 31896115
[TBL] [Abstract][Full Text] [Related]
22. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
Cha W; Jang JY; Wang SG; Kang JH; Jo MG
J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
[TBL] [Abstract][Full Text] [Related]
23. Botulinum toxin injection in the treatment of vocal fold paralysis associated with multiple sclerosis: a case report.
Rontal E; Rontal M; Wald J; Rontal D
J Voice; 1999 Jun; 13(2):274-9. PubMed ID: 10442759
[TBL] [Abstract][Full Text] [Related]
24. Paradoxical Vocal Fold Movement: A Retrospective Analysis.
Vance D; Heyd C; Pier M; Alnouri G; Sataloff RT
J Voice; 2021 Nov; 35(6):927-929. PubMed ID: 32418667
[TBL] [Abstract][Full Text] [Related]
25. Botulinum toxin injections for new onset bilateral vocal fold motion impairment in adults.
Ekbom DC; Garrett CG; Yung KC; Johnson FL; Billante CR; Zealear DL; Courey MS
Laryngoscope; 2010 Apr; 120(4):758-63. PubMed ID: 20213793
[TBL] [Abstract][Full Text] [Related]
26. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
Mendelsohn AH; Berke GS
Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
[TBL] [Abstract][Full Text] [Related]
27. Paradoxical vocal fold motion: presentation and treatment options.
Altman KW; Mirza N; Ruiz C; Sataloff RT
J Voice; 2000 Mar; 14(1):99-103. PubMed ID: 10764121
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of repeated botulinum toxin injections as a function of timing.
Inagi K; Ford CN; Rodriquez AA; Schultz E; Bless DM; Heisey DM
Ann Otol Rhinol Laryngol; 1997 Dec; 106(12):1012-9. PubMed ID: 9415596
[TBL] [Abstract][Full Text] [Related]
29. A prospective crossover trial of botulinum toxin chemodenervation versus injection augmentation for essential voice tremor.
Estes C; Sadoughi B; Coleman R; Sarva H; Mauer E; Sulica L
Laryngoscope; 2018 Feb; 128(2):437-446. PubMed ID: 28988441
[TBL] [Abstract][Full Text] [Related]
30. The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia.
Lundy DS; Lu FL; Casiano RR; Xue JW
J Voice; 1998 Dec; 12(4):460-6. PubMed ID: 9988033
[TBL] [Abstract][Full Text] [Related]
31. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia.
Holden PK; Vokes DE; Taylor MB; Till JA; Crumley RL
Ann Otol Rhinol Laryngol; 2007 Dec; 116(12):891-6. PubMed ID: 18217507
[TBL] [Abstract][Full Text] [Related]
32. Spasmodic dysphonia combined with insufficient glottic closure by phonation.
Kaszás Z; Lichtenberger G; Mészáros K; Falvai J
Eur Arch Otorhinolaryngol; 2003 Sep; 260(8):418-20. PubMed ID: 12709812
[TBL] [Abstract][Full Text] [Related]
33. Botulinum toxin injections for chronic sialorrhoea in children are effective regardless of the degree of neurological dysfunction: A single tertiary institution experience.
Mahadevan M; Gruber M; Bilish D; Edwards K; Davies-Payne D; van der Meer G
Int J Pediatr Otorhinolaryngol; 2016 Sep; 88():142-5. PubMed ID: 27497402
[TBL] [Abstract][Full Text] [Related]
34. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
van Esch BF; Wegner I; Stegeman I; Grolman W
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
[TBL] [Abstract][Full Text] [Related]
35. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.
Blitzer A
Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499
[TBL] [Abstract][Full Text] [Related]
36. Demographic Differences in Clinical Presentation of Pediatric Paradoxical Vocal Fold Motion (PVFM).
Yi JS; Davis AC; Pietsch K; Walsh JM; Scriven KA; Mock J; Ryan MA
J Voice; 2024 Mar; 38(2):539.e1-539.e9. PubMed ID: 34642070
[TBL] [Abstract][Full Text] [Related]
37. Botulinum Toxin in Secondarily Nonresponsive Patients with Spasmodic Dysphonia.
Mor N; Tang C; Blitzer A
Otolaryngol Head Neck Surg; 2016 Sep; 155(3):458-61. PubMed ID: 27143711
[TBL] [Abstract][Full Text] [Related]
38. Botulinum toxin-B injection into the lacrimal gland and posterior cricoarytenoid muscle for the treatment of epiphora and abductor spasmodic dysphonia secondary to Parkinson's disease.
Sachdev A; Costello D; Madge S
Orbit; 2019 Jun; 38(3):248-251. PubMed ID: 29939826
[TBL] [Abstract][Full Text] [Related]
39. Botulinum toxin type A for treating voice tremor.
Adler CH; Bansberg SF; Hentz JG; Ramig LO; Buder EH; Witt K; Edwards BW; Krein-Jones K; Caviness JN
Arch Neurol; 2004 Sep; 61(9):1416-20. PubMed ID: 15364688
[TBL] [Abstract][Full Text] [Related]
40. Abnormal vocal cord movement treated with botulinum toxin in patients with asthma resistant to optimised management.
Baxter M; Uddin N; Raghav S; Leong P; Low K; Hamza K; Holmes PW; Hamilton G; Thyagarajan D; Lau K; Bardin PG
Respirology; 2014 May; 19(4):531-7. PubMed ID: 24655302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
